The successful scale-up and commercialization of biopharmaceuticals is a challenging task that requires a collaboration of professionals from many disciplines. Process simulators can facilitate this task by assisting scientists and engineers to answer the following and other related questions: What is the impact of product titer increase on the capacity load of the downstream section, the overall throughput of a plant, and the cost of goods? What changes are required in an existing multi-product facility to accommodate the process of a new product? What is the range of variability that a process can accommodate if it operates under a tight cycle time? What is the impact of single-use systems on the demand for utilities, the environment and the cost of goods? Our experience in addressing the above questions will be presented using industrial examples in which we evaluated alternative technologies for producing therapeutic monoclonal antibodies and vaccines.
Speaker: Demetri Petrides, PhD., President, INTELLIGEN, INC.
Dr. Petrides is the president of Intelligen, Inc., a software company that develops and markets simulation, design, and scheduling tools for the process manufacturing industries. He has extensive experience in modeling and optimization of biochemical, pharmaceutical, fine chemical and related processes. He has published more than fifty articles and book chapters and given numerous presentations at international conferences and other professional events. He is a member of ACS, AIChE, and ISPE and has co-authored a widely adopted textbook on “Bioseparations Science and Engineering” whose second edition was published by Oxford University Press in February of 2015. Dr. Petrides holds a B.S. from National Technical Univ. of Athens (Greece) and a PhD from MIT, both in chemical engineering
- Log in to post comments